# IL‐17A Promotes NETs Formation via the PKCζ–ERK–ROS–PAD4 Pathway in a Mouse Model of Ischemic Stroke

**Authors:** Chang Liu, Qi Chen, Weijia Chen, Xinyue Han, Xiaowen Qiao, Jun Guo, Wei Su, Qingqing Dai

PMC · DOI: 10.1002/cns.70825 · 2026-03-10

## TL;DR

This study shows how IL-17A worsens brain injury after stroke by promoting neutrophil extracellular traps through a specific molecular pathway.

## Contribution

The study identifies a novel PKCζ–ERK–ROS–PAD4 pathway through which IL-17A promotes NET formation in ischemic stroke.

## Key findings

- IL-17A increases PAD4 and NET formation via the PKCζ–ERK–ROS pathway in stroke.
- Blocking PAD4 or IL-17A reduces infarct size and improves neurological outcomes in mice.
- IL-17A−/− mice and IL-17mAb treatment decrease PAD4, MPO, and CitH3 expression.

## Abstract

Interleukin‐17A (IL‐17A) aggravates poststroke neurological damage and enhances neutrophil extracellular traps (NETs) formation, yet the underlying mechanism remains unclear. This study aimed to elucidate how IL‐17A regulates NETs generation after ischemic stroke.

Using a mouse middle cerebral artery occlusion (MCAO) model, we administered the Peptidylarginine deiminase 4 (PAD4) inhibitor GSK484 or an IL‐17A‐neutralizing antibody (IL‐17mAb). Infarct volume and neurological function were assessed, and protein expression of PAD4, myeloperoxidase (MPO), citrullinated histones H3 (CitH3), protein kinase Cζ (PKCζ), and phosphorylated extracellular signal‐regulated kinase (p‐ERK) was evaluated. IL‐17A−/− mice and primary neutrophils were used to further validate the signaling pathway.

Inhibiting PAD4 with GSK484 can significantly reduce infarct size, improve neurological outcomes, and decrease PAD4, MPO, and CitH3 protein levels. Subsequently, we found that IL‐17mAb treatment can reduce the expression of PAD4, MPO, and CitH3 in the peri‐infarct area, as well as the expression of PKC‐ζ and p‐ERK. Similarly, the expression of PAD4 and CitH3 decreased in the peri‐infarct area of IL‐17A−/− MCAO mice. Finally, we verified IL‐17A induced PAD4 upregulation via the PKCζ–ERK–ROS axis in vitro.

IL‐17A promotes NETs formation by upregulating PAD4 through the PKCζ–ERK–ROS pathway, exacerbating ischemic brain injury. Targeting this axis may offer a novel therapeutic strategy for stroke.

Our study demonstrates that IL‐17A promotes NET formation by upregulating PAD4 through the PKCζ–ERK–ROS pathway, thereby exacerbating ischemic brain injury. IL‐17A regulates NET formation through this newly identified molecular pathway, and targeting this pathway may offer a novel therapeutic strategy for stroke.

## Linked entities

- **Genes:** IL17A (interleukin 17A) [NCBI Gene 3605], PADI4 (peptidyl arginine deiminase 4) [NCBI Gene 23569], MPO (myeloperoxidase) [NCBI Gene 4353], Prkcz (protein kinase C, zeta) [NCBI Gene 18762], EPHB2 (EPH receptor B2) [NCBI Gene 2048]
- **Proteins:** IL17A (interleukin 17A), PADI4 (peptidyl arginine deiminase 4), MPO (myeloperoxidase)
- **Chemicals:** GSK484 (PubChem CID 86340175)
- **Diseases:** ischemic stroke (MONDO:1060198)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, Plat (plasminogen activator, tissue) [NCBI Gene 18791] {aka D8Ertd2e, tPA}, Ly6g (lymphocyte antigen 6 family member G) [NCBI Gene 546644] {aka Gr-1, Gr1, Ly-6G}, Prkcz (protein kinase C, zeta) [NCBI Gene 18762] {aka Pkcz, aPKCzeta, nPKC-zeta, zetaPKC}, Jun (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 16476] {aka AP-1, Junc, c-jun}, Zhx2 (zinc fingers and homeoboxes 2) [NCBI Gene 387609] {aka Afr-1, Afr1, Raf, mKIAA0854}, Cebpb (CCAAT/enhancer binding protein beta) [NCBI Gene 12608] {aka C/EBPbeta, CRP2, IL-6DBP, LAP, LIP, NF-IL6}, Mpo (myeloperoxidase) [NCBI Gene 17523] {aka mKIAA4033}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Padis4 (MMTV LTR integration site 4) [NCBI Gene 110072] {aka Pad4}, Cort (cortistatin) [NCBI Gene 12854] {aka CST, PCST}, Hspg2 (perlecan (heparan sulfate proteoglycan 2)) [NCBI Gene 15530] {aka HSPG, Pcn, Plc, per}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, MPO (myeloperoxidase) [NCBI Gene 4353], ELANE (elastase, neutrophil expressed) [NCBI Gene 1991] {aka ELA2, GE, HLE, HNE, NE, PMN-E}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, Eif2ak3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 13666] {aka Pek, Perk}, Mdk (midkine) [NCBI Gene 17242] {aka MK, Mek}, Dusp1 (dual specificity phosphatase 1) [NCBI Gene 19252] {aka 3CH134, MKP1, Ptpn16, erp, mkp-1}
- **Diseases:** death (MESH:D003643), venous thromboembolism (MESH:D054556), ischemic brain injury (MESH:D001930), neurological damage (MESH:D020196), ataxia (MESH:D001259), MCAO (MESH:D020244), brain damage (MESH:D001925), BBB damage (MESH:C538387), hypokinesia (MESH:D018476), tremor (MESH:D014202), decreased muscle strength (MESH:D009123), inflammation (MESH:D007249), reperfusion injury (MESH:D015427), thrombosis (MESH:D013927), neurological defect (MESH:D009421), reduced body tone (MESH:C567468), bone destruction (MESH:D001847), pancreatitis (MESH:D010195), brain infarcts (MESH:D020520), Cerebral Infarction (MESH:D002544), cancer (MESH:D009369), R (MESH:C580424), diabetes (MESH:D003920), brain ischemia (MESH:D002545), kyphosis (MESH:D007738), neurobehavioral deficits (MESH:D019954), neurological function loss (MESH:D003291), pneumonia (MESH:D011014), Stroke (MESH:D020521), brain hemorrhage (MESH:D020300), NETs (MESH:C536657), brain edema (MESH:D001929), Infarct (MESH:D007238), cognitive decline (MESH:D003072), motor impairment (MESH:D000068079), twitch (MESH:D013746), convulsion (MESH:D012640), neurological deficits (MESH:D009461), acute (MESH:D000208), respiratory distress (MESH:D012128)
- **Chemicals:** 2,3,5-Triphenyltetrazolium chloride (MESH:C009591), DCF (MESH:D015649), HY-100514 (-), polyacrylamide (MESH:C016679), sodium pentobarbital (MESH:D010424), Apocynin (MESH:C056165), FITC (MESH:D016650), EDTA (MESH:D004492), cysteine (MESH:D003545), DCFH-DA (MESH:C029569), water (MESH:D014867), Ravoxertinib (MESH:C000619637), DMSO (MESH:D004121), DAPI (MESH:C007293), ROS (MESH:D017382), PBS (MESH:D007854), heparin (MESH:D006493), polyvinylidene difluoride (MESH:C024865), SDS (MESH:D012967)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** S0033S
- **Cell lines:** C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12973334/full.md

---
Source: https://tomesphere.com/paper/PMC12973334